Shopping Cart 0
Cart Subtotal
USD 0

Global Non-invasive Prenatal Testing (NIPT) Market Forecast to 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global Non-invasive Prenatal Testing (NIPT) Market: Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[83 pages report] This market research report includes a detailed segmentation of the global non-invasive prenatal testing market-By Application (Trisomy, Microdeletion Syndrome, and Other NIPT Applications), and By Region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Non-invasive Prenatal Testing Market Research
Infoholic's market research report predicts that the global non-invasive prenatal testing market will grow at a CAGR of 17.5% during the forecast period 2019-2025. The market has witnessed steady growth in the past few years and development in technology with the introduction of advanced products has increased the acceptance of non-invasive prenatal testing products in the market. The market is fueled by an upsurge in the number of newborns with chromosomal disorders due to the increasing number of late pregnancies and growing demand for non-invasive procedures for early diagnosis.
 
The global market continues to grow, and NIPT is among the most widely used techniques for detecting genetic disorders in the fetal stage, which will help in the proper management of disease during the initial period of the gestation. The field is getting revolutionized with the advancement in technology. Vendors are focusing on new product launches, product approvals, and targeting end-user's perspective. The market generates revenue from the key players operating in this field, and few of them include Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., F. Hoffmann-La Roche Ltd., and Beijing Genomics Institute.
According to Infoholic Research analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide. The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24-25 years with incidence rate reduced to 1 in 1429. The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, the presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and the presence of a huge population base.
By Application:
Trisomy
Microdeletion Syndrome
Other NIPT Applications
In 2018, the trisomy segment occupied the largest share and is expected to grow at a high CAGR during the forecast period. Increasing incidence of chromosomal anomalies coupled with advanced maternal age makes the segment the major shareholder in the global non-invasive prenatal testing market. Further, innovations in technology are likely to propel the growth of the segment during the forecast period.
By Regions:
North America
Europe
APAC
RoW
The global market is dominated by North America, followed by Europe and the Asia Pacific. The US occupied the dominant share in the North American market due to the increasing adoption of high- and average-risk NIPT test, rising number of late pregnancies that increase the number of newborns with Down syndrome, no risk of miscarriage, and availability of the advanced tests due to the presence of dominant vendors in the region.
Non-Invasive Prenatal Testing Market Research Competitive Analysis-The global non-invasive prenatal testing market has massive growth opportunities in both developed and developing regions. The advancements of tests will increase the competition among vendors. The increased focus of diagnostics and biotechnology companies has led to an increase in deals related to non-invasive testing products due to its increasing popularity. 10x Genomics Inc. and Berry Genomics Co. Ltd. entered into a collaboration to further develop approaches for next-generation NIPT in January 2018. In early 2018, IONA test developed by Premaitha Health plc has been approved by Brazil's regulatory authority, Agencia Nacional de Vigilancia Sanitaria, for sale in the country as an IVD. In late 2018, PerkinElmer's Vanadis NIPT system obtained CE-IVD mark for commercialization and distribution in Europe and in other countries where CE-IVD mark is accepted. The key market vendors are focusing on increasing the product portfolio. There are few acquisitions in the last few years. Premaitha acquired Yourgene Bioscience in Taiwan in March 2017. In July 2017, Eurofins Scientific closed the acquisition of GATC Biotech AG and this transaction comprises the acquisition of 62.63% of the shares owned by GATC in LifeCodexx AG, one of Europe's specialists in NIPT. In addition, other leading players are focusing on hugely investing in R&D activities to develop new products to attain a maximum share in the market.
Key vendors:
Natera Inc.
Laboratory Corporation of America Holdings (LabCorp)
Illumina Inc.
F. Hoffmann-La Roche
Beijing Genomics Institute
LifeCodexx AG
Quest Diagnostics
Yourgene Health Plc
Myriad Genetics Inc.
NIPD Genetics
PerkinElmer Inc.
Next Biosciences (Pty) Limited
Key competitive facts:
The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
The requirement of high initial investment, implementation, and maintenance cost in the market are also limiting the entry of new players.
Benefits-The report provides complete details about the adoption rate of non-invasive prenatal tests. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
Understanding the potential market opportunity with precise market size and forecast data.
A detailed market analysis focusing on the growth of the non-invasive prenatal testing industry.
Factors influencing the growth of the non-invasive prenatal testing market.
In-depth competitive analysis of dominant and pure-play vendors.
Prediction analysis of the non-invasive prenatal testing industry in both developed and developing regions.
Key insights related to major segments of the non-invasive prenatal testing market.
Latest market trend analysis impacting the buying behavior of the consumers.
 
Key Stakeholders
READ MORE

Table Of Content

Scope

Table of Contents

1 INDUSTRY OUTLOOK 8

1.1 Industry overview 8

1.2 Total addressable market 8

1.3 Industry Trends 9

2 Report Outline 10

2.1 Report Scope 10

2.2 Report Summary 10

2.3 Research Methodology 11

2.4 Report Assumptions 11

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Advantages of genetic testing 13

3.3 Disadvantage of genetic testing 13

3.4 Segmented Addressable Market (SAM) 13

3.5 Trends of the genetic testing market 14

3.6 Related Markets 15

3.6.1 Point-Of-Care Diagnostics 15

3.6.2 Liquid biopsy 15

3.6.3 Transplantation diagnostics 16

3.6.4 Cell-free DNA testing 16

4 Market Outlook 17

4.1 Funding Scenario 17

4.2 Market segmentation 18

4.3 PEST Analysis 18

4.4 Porter 5(Five) Forces 19

5 Market Characteristics 21

5.1 DRO-Global Genetic Testing Market Dynamics 21

5.1.1 Drivers 21

5.1.1.1 Increasing incidence of disease across the globe 21

5.1.1.2 Upsurge in the demand for personalized medicine 22

5.1.1.3 Growing emphasis on early disease detection 22

5.1.2 Opportunities 23

5.1.2.1 Upsurge in healthcare spending and growing healthcare awareness in emerging countries 23

5.1.2.2 Increase in collaborations 23

5.1.3 Restraints 24

5.1.3.1 High test cost 24

5.1.3.2 Ethical issues related to genetic testing 24

5.2 DRO-Impact Analysis 25

5.3 Key Stakeholders 26

6 Test Type: Market Size and Analysis 28

6.1 Overview 28

6.2 Diagnostic testing 29

6.3 Prenatal and newborn testing 30

6.4 Predictive and presymptomatic screening 31

6.5 Others 33

7 Regions: Market Size and Analysis 35

7.1 Overview 35

7.2 North America 36

7.3 Europe 38

7.4 Asia Pacific 39

7.5 Rest of the World 40

8 Competitive Landscape 43

8.1 Overview 43

9 Vendor Profiles 46

9.1 Qiagen N.V. 46

9.1.1 Overview 46

9.1.2 Geographic Presence 52

9.1.3 Business Focus 53

9.1.4 SWOT Analysis 54

9.1.5 Business Strategies 54

9.2 F. Hoffmann-La Roche Ltd 55

9.2.1 Overview 55

9.2.2 Business Units 58

9.2.3 Geographic Presence 58

9.2.4 Business Focus 59

9.2.5 SWOT Analysis 59

9.2.6 Business Strategies 60

9.3 ABBOTT LABORATORIES 61

9.3.1 Overview 61

9.3.2 Business Unit 64

9.3.3 Geographic Presence 65

9.3.4 Business Focus 66

9.3.5 SWOT Analysis 67

9.3.6 Business Strategy 67

9.4 Illumina, Inc. 68

9.4.1 Overview 68

9.4.2 Business Units 74

9.4.3 Geographic Presence 75

9.4.4 Business Focus 76

9.4.5 SWOT Analysis 76

9.4.6 Business Strategy 77

9.5 Quest Diagnostics 77

9.5.1 Overview 77

9.5.2 Business Units 82

9.5.3 Business Focus 83

9.5.4 SWOT Analysis 83

9.5.5 Business Strategy 84

10 Companies to Watch For 85

10.1 Natera, Inc. 85

10.1.1 Overview 85

10.2 Myriad Genetics 86

10.2.1 Overview 86

10.3 Bio-Rad Laboratories 88

10.3.1 Overview 88

10.3.2 Bio-Rad laboratories: Recent Developments 89

10.4 bioMerieux S.A. 90

10.4.1 Overview 90

10.4.2 BioMerieux S.A.: Recent Developments 90

10.5 Luminex Corporation 91

10.5.1 Overview 91

10.5.2 Luminex Corporation: Recent Developments 92

10.6 Cepheid (Danaher Corporation) 93

10.6.1 Overview 93

10.6.2 Cepheid (Danaher Corporation): Recent Developments 94

10.7 Laboratory Corporation of America Holdings 95

10.7.1 Overview 95

10.7.2 Laboratory Corporation of America Holdings: Recent Developments 96

11 Annexure 97

11.1 Abbreviations 97

 

 

 

 


List Of Figure

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 12

CHART 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE, 2018-2025 (USD MILLION) 15

CHART 3 SEGMENTATION OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 18

CHART 4 PEST ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 19

CHART 5 PORTER 5 FORCES ON GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 20

CHART 6 MARKET DYNAMICS-DRO ANALYSIS 22

CHART 7 DRO-IMPACT ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 25

CHART 8 KEY STAKEHOLDERS 26

CHART 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2018 (%) 28

CHART 10 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2025 (%) 28

CHART 11 TRISOMY MARKET FORECAST, 2018-2025 (USD MILLION) 29

CHART 12 MICRODELETION SYNDROME MARKET FORECAST, 2018-2025 (USD MILLION) 31

CHART 13 OTHER NIPT APPLICATIONS MARKET FORECAST, 2018-2025 (USD MILLION) 32

CHART 14 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 33

CHART 15 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 33

CHART 16 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN NORTH AMERICA, 2018-2025 (USD MILLION) 35

CHART 17 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN EUROPE, 2018-2025 (USD MILLION) 36

CHART 18 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN ASIA PACIFIC, 2018-2025 (USD MILLION) 38

CHART 19 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN REST OF THE WORLD, 2018-2025 (USD MILLION) 39

CHART 20 NATERA INC.: OVERVIEW SNAPSHOT 44

CHART 21 NATERA INC.: GEOGRAPHIC PRESENCE 44

CHART 22 NATERA INC.: SWOT ANALYSIS 45

CHART 23 ILLUMINA INC.: OVERVIEW SNAPSHOT 52

CHART 24 ILLUMINA INC.: BUSINESS UNITS 52

CHART 25 ILLUMINA INC.: GEOGRAPHIC PRESENCE 53

CHART 26 ILLUMINA INC.: SWOT ANALYSIS 54

CHART 27 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT 57

CHART 28 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS 58

CHART 29 LABORATORY CORPORATION OF AMERICA HOLDINGS: GEOGRAPHIC PRESENCE 58

CHART 30 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 59

CHART 31 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 62

CHART 32 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 63

CHART 33 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC PRESENCE 64

CHART 34 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 65

CHART 35 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS 68

 


List Of Table

Tables

TABLE 1 FUNDING SCENARIO 18

TABLE 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE BY REGIONS, 2018-2025 (USD MILLION) 34

TABLE 3 OTHER PROMINENT VENDORS IN THE NON-INVASIVE PRENATAL TESTING MARKET 41

TABLE 4 NATERA INC.: OFFERINGS 42

TABLE 5 NATERA INC.: RECENT DEVELOPMENTS 42

TABLE 6 ILLUMINA INC.: PRODUCT OFFERINGS 47

TABLE 7 ILLUMINA INC.: RECENT DEVELOPMENTS 47

TABLE 8 LABORATORY CORPORATION OF AMERICA HOLDINGS: OFFERINGS 56

TABLE 9 LABORATORY CORPORATION OF AMERICA HOLDINGS: RECENT DEVELOPMENTS 56

TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 61

TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 61

TABLE 12 BEIJING GENOMICS INSTITUTE: PRODUCT OFFERINGS 67

TABLE 13 BEIJING GENOMICS INSTITUTE: RECENT DEVELOPMENTS 67

TABLE 14 QUEST DIAGNOSTICS: SNAPSHOT 70

TABLE 15 QUEST DIAGNOSTICS: RECENT DEVELOPMENTS 70

TABLE 16 LIFECODEXX AG: SNAPSHOT 73

TABLE 17 LIFECODEXX AG: RECENT DEVELOPMENTS 73

TABLE 18 YOUR GENE HEALTH PLC: SNAPSHOT 75

TABLE 19 YOUR GENE HEALTH PLC: RECENT DEVELOPMENTS 75

TABLE 20 NIPD GENETICS: SNAPSHOT 76

TABLE 21 NIPD GENETICS: RECENT DEVELOPMENTS 76

TABLE 22 MYRIAD GENETICS INC.: SNAPSHOT 77

TABLE 23 MYRIAD GENETICS INC.: RECENT DEVELOPMENTS 77

TABLE 24 PerkinElmer INC.: SNAPSHOT 79

TABLE 25 PerkinElmer INC.: RECENT DEVELOPMENTS 79

TABLE 26 NEXT BIOSCIENCES (PTY) LIMITED: SNAPSHOT 80

TABLE 27 NEXT BIOSCIENCES (PTY) LIMITED: RECENT DEVELOPMENTS 80

 

?

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Natera Inc.

Laboratory Corporation of America Holdings (LabCorp)

Illumina Inc.

Hoffmann-La Roche

Beijing Genomics Institute

LifeCodexx AG

Quest Diagnostics

Yourgene Health Plc

Myriad Genetics Inc.

NIPD Genetics

PerkinElmer Inc.

Next Biosciences (Pty) Limited

Global Non-invasive Prenatal Testing (NIPT) Market: Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[83 pages report] This market research report includes a detailed segmentation of the global non-invasive prenatal testing market-By Application (Trisomy, Microdeletion Syndrome, and Other NIPT Applications), and By Region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Non-invasive Prenatal Testing Market Research
Infoholic's market research report predicts that the global non-invasive prenatal testing market will grow at a CAGR of 17.5% during the forecast period 2019-2025. The market has witnessed steady growth in the past few years and development in technology with the introduction of advanced products has increased the acceptance of non-invasive prenatal testing products in the market. The market is fueled by an upsurge in the number of newborns with chromosomal disorders due to the increasing number of late pregnancies and growing demand for non-invasive procedures for early diagnosis.
 
The global market continues to grow, and NIPT is among the most widely used techniques for detecting genetic disorders in the fetal stage, which will help in the proper management of disease during the initial period of the gestation. The field is getting revolutionized with the advancement in technology. Vendors are focusing on new product launches, product approvals, and targeting end-user's perspective. The market generates revenue from the key players operating in this field, and few of them include Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., F. Hoffmann-La Roche Ltd., and Beijing Genomics Institute.
According to Infoholic Research analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide. The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24-25 years with incidence rate reduced to 1 in 1429. The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, the presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and the presence of a huge population base.
By Application:
Trisomy
Microdeletion Syndrome
Other NIPT Applications
In 2018, the trisomy segment occupied the largest share and is expected to grow at a high CAGR during the forecast period. Increasing incidence of chromosomal anomalies coupled with advanced maternal age makes the segment the major shareholder in the global non-invasive prenatal testing market. Further, innovations in technology are likely to propel the growth of the segment during the forecast period.
By Regions:
North America
Europe
APAC
RoW
The global market is dominated by North America, followed by Europe and the Asia Pacific. The US occupied the dominant share in the North American market due to the increasing adoption of high- and average-risk NIPT test, rising number of late pregnancies that increase the number of newborns with Down syndrome, no risk of miscarriage, and availability of the advanced tests due to the presence of dominant vendors in the region.
Non-Invasive Prenatal Testing Market Research Competitive Analysis-The global non-invasive prenatal testing market has massive growth opportunities in both developed and developing regions. The advancements of tests will increase the competition among vendors. The increased focus of diagnostics and biotechnology companies has led to an increase in deals related to non-invasive testing products due to its increasing popularity. 10x Genomics Inc. and Berry Genomics Co. Ltd. entered into a collaboration to further develop approaches for next-generation NIPT in January 2018. In early 2018, IONA test developed by Premaitha Health plc has been approved by Brazil's regulatory authority, Agencia Nacional de Vigilancia Sanitaria, for sale in the country as an IVD. In late 2018, PerkinElmer's Vanadis NIPT system obtained CE-IVD mark for commercialization and distribution in Europe and in other countries where CE-IVD mark is accepted. The key market vendors are focusing on increasing the product portfolio. There are few acquisitions in the last few years. Premaitha acquired Yourgene Bioscience in Taiwan in March 2017. In July 2017, Eurofins Scientific closed the acquisition of GATC Biotech AG and this transaction comprises the acquisition of 62.63% of the shares owned by GATC in LifeCodexx AG, one of Europe's specialists in NIPT. In addition, other leading players are focusing on hugely investing in R&D activities to develop new products to attain a maximum share in the market.
Key vendors:
Natera Inc.
Laboratory Corporation of America Holdings (LabCorp)
Illumina Inc.
F. Hoffmann-La Roche
Beijing Genomics Institute
LifeCodexx AG
Quest Diagnostics
Yourgene Health Plc
Myriad Genetics Inc.
NIPD Genetics
PerkinElmer Inc.
Next Biosciences (Pty) Limited
Key competitive facts:
The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
The requirement of high initial investment, implementation, and maintenance cost in the market are also limiting the entry of new players.
Benefits-The report provides complete details about the adoption rate of non-invasive prenatal tests. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
Understanding the potential market opportunity with precise market size and forecast data.
A detailed market analysis focusing on the growth of the non-invasive prenatal testing industry.
Factors influencing the growth of the non-invasive prenatal testing market.
In-depth competitive analysis of dominant and pure-play vendors.
Prediction analysis of the non-invasive prenatal testing industry in both developed and developing regions.
Key insights related to major segments of the non-invasive prenatal testing market.
Latest market trend analysis impacting the buying behavior of the consumers.
 
Key Stakeholders
READ MORE

Scope

Table of Contents

1 INDUSTRY OUTLOOK 8

1.1 Industry overview 8

1.2 Total addressable market 8

1.3 Industry Trends 9

2 Report Outline 10

2.1 Report Scope 10

2.2 Report Summary 10

2.3 Research Methodology 11

2.4 Report Assumptions 11

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Advantages of genetic testing 13

3.3 Disadvantage of genetic testing 13

3.4 Segmented Addressable Market (SAM) 13

3.5 Trends of the genetic testing market 14

3.6 Related Markets 15

3.6.1 Point-Of-Care Diagnostics 15

3.6.2 Liquid biopsy 15

3.6.3 Transplantation diagnostics 16

3.6.4 Cell-free DNA testing 16

4 Market Outlook 17

4.1 Funding Scenario 17

4.2 Market segmentation 18

4.3 PEST Analysis 18

4.4 Porter 5(Five) Forces 19

5 Market Characteristics 21

5.1 DRO-Global Genetic Testing Market Dynamics 21

5.1.1 Drivers 21

5.1.1.1 Increasing incidence of disease across the globe 21

5.1.1.2 Upsurge in the demand for personalized medicine 22

5.1.1.3 Growing emphasis on early disease detection 22

5.1.2 Opportunities 23

5.1.2.1 Upsurge in healthcare spending and growing healthcare awareness in emerging countries 23

5.1.2.2 Increase in collaborations 23

5.1.3 Restraints 24

5.1.3.1 High test cost 24

5.1.3.2 Ethical issues related to genetic testing 24

5.2 DRO-Impact Analysis 25

5.3 Key Stakeholders 26

6 Test Type: Market Size and Analysis 28

6.1 Overview 28

6.2 Diagnostic testing 29

6.3 Prenatal and newborn testing 30

6.4 Predictive and presymptomatic screening 31

6.5 Others 33

7 Regions: Market Size and Analysis 35

7.1 Overview 35

7.2 North America 36

7.3 Europe 38

7.4 Asia Pacific 39

7.5 Rest of the World 40

8 Competitive Landscape 43

8.1 Overview 43

9 Vendor Profiles 46

9.1 Qiagen N.V. 46

9.1.1 Overview 46

9.1.2 Geographic Presence 52

9.1.3 Business Focus 53

9.1.4 SWOT Analysis 54

9.1.5 Business Strategies 54

9.2 F. Hoffmann-La Roche Ltd 55

9.2.1 Overview 55

9.2.2 Business Units 58

9.2.3 Geographic Presence 58

9.2.4 Business Focus 59

9.2.5 SWOT Analysis 59

9.2.6 Business Strategies 60

9.3 ABBOTT LABORATORIES 61

9.3.1 Overview 61

9.3.2 Business Unit 64

9.3.3 Geographic Presence 65

9.3.4 Business Focus 66

9.3.5 SWOT Analysis 67

9.3.6 Business Strategy 67

9.4 Illumina, Inc. 68

9.4.1 Overview 68

9.4.2 Business Units 74

9.4.3 Geographic Presence 75

9.4.4 Business Focus 76

9.4.5 SWOT Analysis 76

9.4.6 Business Strategy 77

9.5 Quest Diagnostics 77

9.5.1 Overview 77

9.5.2 Business Units 82

9.5.3 Business Focus 83

9.5.4 SWOT Analysis 83

9.5.5 Business Strategy 84

10 Companies to Watch For 85

10.1 Natera, Inc. 85

10.1.1 Overview 85

10.2 Myriad Genetics 86

10.2.1 Overview 86

10.3 Bio-Rad Laboratories 88

10.3.1 Overview 88

10.3.2 Bio-Rad laboratories: Recent Developments 89

10.4 bioMerieux S.A. 90

10.4.1 Overview 90

10.4.2 BioMerieux S.A.: Recent Developments 90

10.5 Luminex Corporation 91

10.5.1 Overview 91

10.5.2 Luminex Corporation: Recent Developments 92

10.6 Cepheid (Danaher Corporation) 93

10.6.1 Overview 93

10.6.2 Cepheid (Danaher Corporation): Recent Developments 94

10.7 Laboratory Corporation of America Holdings 95

10.7.1 Overview 95

10.7.2 Laboratory Corporation of America Holdings: Recent Developments 96

11 Annexure 97

11.1 Abbreviations 97

 

 

 

 


List Of Figure

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 12

CHART 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE, 2018-2025 (USD MILLION) 15

CHART 3 SEGMENTATION OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 18

CHART 4 PEST ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 19

CHART 5 PORTER 5 FORCES ON GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 20

CHART 6 MARKET DYNAMICS-DRO ANALYSIS 22

CHART 7 DRO-IMPACT ANALYSIS OF GLOBAL NON-INVASIVE PRENATAL TESTING MARKET 25

CHART 8 KEY STAKEHOLDERS 26

CHART 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2018 (%) 28

CHART 10 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY APPLICATION SEGMENTATION, 2025 (%) 28

CHART 11 TRISOMY MARKET FORECAST, 2018-2025 (USD MILLION) 29

CHART 12 MICRODELETION SYNDROME MARKET FORECAST, 2018-2025 (USD MILLION) 31

CHART 13 OTHER NIPT APPLICATIONS MARKET FORECAST, 2018-2025 (USD MILLION) 32

CHART 14 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 33

CHART 15 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 33

CHART 16 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN NORTH AMERICA, 2018-2025 (USD MILLION) 35

CHART 17 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN EUROPE, 2018-2025 (USD MILLION) 36

CHART 18 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN ASIA PACIFIC, 2018-2025 (USD MILLION) 38

CHART 19 NON-INVASIVE PRENATAL TESTING MARKET REVENUE IN REST OF THE WORLD, 2018-2025 (USD MILLION) 39

CHART 20 NATERA INC.: OVERVIEW SNAPSHOT 44

CHART 21 NATERA INC.: GEOGRAPHIC PRESENCE 44

CHART 22 NATERA INC.: SWOT ANALYSIS 45

CHART 23 ILLUMINA INC.: OVERVIEW SNAPSHOT 52

CHART 24 ILLUMINA INC.: BUSINESS UNITS 52

CHART 25 ILLUMINA INC.: GEOGRAPHIC PRESENCE 53

CHART 26 ILLUMINA INC.: SWOT ANALYSIS 54

CHART 27 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT 57

CHART 28 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS 58

CHART 29 LABORATORY CORPORATION OF AMERICA HOLDINGS: GEOGRAPHIC PRESENCE 58

CHART 30 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 59

CHART 31 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 62

CHART 32 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 63

CHART 33 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC PRESENCE 64

CHART 34 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 65

CHART 35 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS 68

 


List Of Table

Tables

TABLE 1 FUNDING SCENARIO 18

TABLE 2 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE BY REGIONS, 2018-2025 (USD MILLION) 34

TABLE 3 OTHER PROMINENT VENDORS IN THE NON-INVASIVE PRENATAL TESTING MARKET 41

TABLE 4 NATERA INC.: OFFERINGS 42

TABLE 5 NATERA INC.: RECENT DEVELOPMENTS 42

TABLE 6 ILLUMINA INC.: PRODUCT OFFERINGS 47

TABLE 7 ILLUMINA INC.: RECENT DEVELOPMENTS 47

TABLE 8 LABORATORY CORPORATION OF AMERICA HOLDINGS: OFFERINGS 56

TABLE 9 LABORATORY CORPORATION OF AMERICA HOLDINGS: RECENT DEVELOPMENTS 56

TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 61

TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 61

TABLE 12 BEIJING GENOMICS INSTITUTE: PRODUCT OFFERINGS 67

TABLE 13 BEIJING GENOMICS INSTITUTE: RECENT DEVELOPMENTS 67

TABLE 14 QUEST DIAGNOSTICS: SNAPSHOT 70

TABLE 15 QUEST DIAGNOSTICS: RECENT DEVELOPMENTS 70

TABLE 16 LIFECODEXX AG: SNAPSHOT 73

TABLE 17 LIFECODEXX AG: RECENT DEVELOPMENTS 73

TABLE 18 YOUR GENE HEALTH PLC: SNAPSHOT 75

TABLE 19 YOUR GENE HEALTH PLC: RECENT DEVELOPMENTS 75

TABLE 20 NIPD GENETICS: SNAPSHOT 76

TABLE 21 NIPD GENETICS: RECENT DEVELOPMENTS 76

TABLE 22 MYRIAD GENETICS INC.: SNAPSHOT 77

TABLE 23 MYRIAD GENETICS INC.: RECENT DEVELOPMENTS 77

TABLE 24 PerkinElmer INC.: SNAPSHOT 79

TABLE 25 PerkinElmer INC.: RECENT DEVELOPMENTS 79

TABLE 26 NEXT BIOSCIENCES (PTY) LIMITED: SNAPSHOT 80

TABLE 27 NEXT BIOSCIENCES (PTY) LIMITED: RECENT DEVELOPMENTS 80

 

?

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Natera Inc.

Laboratory Corporation of America Holdings (LabCorp)

Illumina Inc.

Hoffmann-La Roche

Beijing Genomics Institute

LifeCodexx AG

Quest Diagnostics

Yourgene Health Plc

Myriad Genetics Inc.

NIPD Genetics

PerkinElmer Inc.

Next Biosciences (Pty) Limited

chat_bubbleLet's Chat